LLukas22/scidocs huggingface dataset:
Intertester reliability of the talk test in a cardiac rehabilitation population.

PURPOSE
The validity of the Talk Test (TT) is well documented, but the reliability of the test is not clear. The aim of this study was to assess the absolute and relative intertester reliability of the TT in cardiac patients.


METHODS
Cardiac patients (n = 64) who had completed an exercise rehabilitation program were consecutively included in the study. Patients performed a submaximal ramp cycle ergometer test with the TT as intensity indicator. Every patient was tested twice on the same day by 2 different physiotherapists with a break of maximum 45 minutes between tests. Physiotherapists were randomized to tests. Workload in watts at the first negative stage of the TT was registered as the test result. Patients and physiotherapists were blinded to test results of the first test. Absolute reliability of the TT was assessed with Bland-Altman plot, standard error of measurement, and minimal detectable change. Relative reliability was assessed using the intraclass correlation coefficient (ICC).


RESULTS
Mean difference in peak workload between test and retest was 0.8 W (95% CI: -4.8 to 3.3). Limit of agreement was estimated to be +31/-32 W. Standard error of measurement was 11 W (95% CI: 10-14), and minimal detectable change was 32 W. The ICC was 0.85 (95% CI: 0.78 to 0.91).


CONCLUSIONS
Although the ICC was acceptable, we found a weak absolute intertester reliability of the TT and that the test is an insufficient measure to monitor exercise intensity and safety of cardiac patients when 2 or more physiotherapists may be administering the TT.
' SMART ’ CANE FOR THE VISUALLY IMPAIRED : DESIGN AND CONTROLLED FIELD TESTING OF AN AFFORDABLE OBSTACLE DETECTION SYSTEM

(USA) respectively. Since graduation, they have been associated with this project in voluntary and individual capacity. Sandeep Singh Gujral, an occupational therapist was an intern at the IIT Delhi from August-November 2009 and conducted user training for the trials.
Cerebral palsy and intrauterine growth in single births: European collaborative study

BACKGROUND
Cerebral palsy seems to be more common in term babies whose birthweight is low for their gestational age at delivery, but past analyses have been hampered by small datasets and Z-score calculation methods.


METHODS
We compared data from ten European registers for 4503 singleton children with cerebral palsy born between 1976 and 1990 with the number of births in each study population. Weight and gestation of these children were compared with reference standards for the normal spread of gestation and weight-for-gestational age at birth.


FINDINGS
Babies of 32-42 weeks' gestation with a birthweight for gestational age below the 10th percentile (using fetal growth standards) were 4-6 times more likely to have cerebral palsy than were children in a reference band between the 25th and 75th percentiles. In children with a weight above the 97th percentile, the increased risk was smaller (from 1.6 to 3.1), but still significant. Those with a birthweight about 1 SD above average always had the lowest risk of cerebral palsy. A similar pattern was seen in those with unilateral or bilateral spasticity, as in those with a dyskinetic or ataxic disability. In babies of less than 32 weeks' gestation, the relation between weight and risk was less clear.


INTERPRETATION
The risk of cerebral palsy, like the risk of perinatal death, is lowest in babies who are of above average weight-for-gestation at birth, but risk rises when weight is well above normal as well as when it is well below normal. Whether deviant growth is the cause or a consequence of the disability remains to be determined.
Improving attendance for breast screening among recent non-attenders: a randomised controlled trial of two interventions in primary care.

OBJECTIVES
To examine the effectiveness and cost-effectiveness of two primary care based interventions aimed at increasing breast screening uptake for women who had recently failed to attend.


SETTING
13 General practices with low uptake in the second round of breast screening (below 60%) in north west London and the West Midlands, United Kingdom. Participants were women in these practices who were recent non-attenders for breast screening in the third round.


METHODS
Pragmatic factorial randomised controlled trial, with people randomised to a systematic intervention (general practitioner letter), an opportunistic intervention (flag in women's notes prompting discussion by health professionals), neither intervention, or both. Outcome measures were attendance for screening 6 months after randomisation and cost-effectiveness of the interventions.


RESULTS
1,158 Women were individually randomised as follows: 289 control; 291 letter; 290 flag; 288 both interventions. Attendance was ascertained for 1,148 (99%) of the 1,158 women. Logistic regression adjusting for the other intervention and practice produced an odds ratio (OR) for attendance of 1.51 (95% confidence interval (95% CI 1.02 to 2.26; p=0.04) for the letter, and 1.39 (95% CI 0.93 to 2.07; p=0.10) for the flag. Health service costs/ additional attendance were 35 pounds (letter) and 65 pounds (flag).


CONCLUSIONS
Among recent non-attenders, the letter was effective in increasing breast screening attendance. The flag was of equivocal effectiveness and was considerably less cost-effective than the letter.
4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention

OBJECTIVES
The aim of the study was to investigate 4-year outcomes and predictors of repeat revascularization in patients treated with the Resolute zotarolimus-eluting stent (R-ZES) (Medtronic, Minneapolis, Minnesota) and XIENCE V everolimus-eluting stent (EES) (Abbott Vascular, Abbott Park, Illinois) in the RESOLUTE (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention) All-Comers trial.


BACKGROUND
Data on long-term outcomes of new-generation drug-eluting stents are limited, and predictors of repeat revascularization due to restenosis and/or progression of disease are largely unknown.


METHODS
Patients were randomly assigned to treatment with the R-ZES (n = 1,140) or the EES (n = 1,152). We assessed pre-specified safety and efficacy outcomes at 4 years including target lesion failure and stent thrombosis. Predictors of revascularization at 4 years were identified by Cox regression analysis.


RESULTS
At 4 years, the rates of target lesion failure (15.2% vs. 14.6%, p = 0.68), cardiac death (5.4% vs. 4.7%, p = 0.44), and target vessel myocardial infarction (5.3% vs. 5.4%, p = 1.00), clinically-indicated target lesion revascularization (TLR) (7.0% vs. 6.5%, p = 0.62), and definite/probable stent thrombosis (2.3% vs. 1.6%, p = 0.23) were similar with the R-ZES and EES. Independent predictors of TLR were age, insulin-treated diabetes, SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score, treatment of saphenous vein grafts, ostial lesions, and in-stent restenosis. Independent predictors of any revascularization were age, diabetes, previous percutaneous coronary intervention, absence of ST-segment elevation myocardial infarction, smaller reference vessel diameter, SYNTAX score, and treatment of left anterior descending, right coronary artery, saphenous vein grafts, ostial lesions, or in-stent restenosis.


CONCLUSIONS
R-ZES and EES demonstrated similar safety and efficacy throughout 4 years. TLR represented less than one-half of all repeat revascularization procedures. Patient- and lesion-related factors predicting the risk of TLR and any revascularization showed considerable overlap. (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention [RESOLUTE-AC]; NCT00617084).
Les tumeurs malignes anorectales en milieu hospitalier à Ouagadougou: aspects épidémiologiques et diagnostiques

Le but de notre étude était de décrire les caractéristiques épidémiologiques et diagnostiques des tumeurs malignes anorectales en milieu hospitalier à Ouagadougou. Il s'est agi d'une étude rétrospective et transversale qui a concerné les patients vus en endoscopie digestive basse au cours de la période allant du 29/09/1999 au 04/10/2008. À l'aide d'une fiche de collecte, nous avons recueilli, dans 4 structures sanitaires et 3 laboratoires d'anatomie et de cytologie pathologiques de la ville de Ouagadougou, les données à partir des comptes-rendus d'endoscopie digestive basse et des registres d'anatomie et de cytologie pathologiques. Durant la période de notre étude, 645 patients ont été examinés en anorectoscopie et 882 cas d'affections anorectales colligés. Les tumeurs malignes anorectales avec 61 cas (6,9%) occupaient la quatrième place après la maladie hémorroïdaire (45,6%), les anites (21,1%) et les fissures (13,9%). Elles regroupaient les cancers du rectum (4,2%) et les cancers de l'anus (2,7%). Vingt cancers anorectaux ont été histologiquement confirmés parmi lesquels l'adénocarcinome était le type histologique le plus retrouvé avec 17 cas. Les tumeurs malignes, quatrième affection anorectale la plus fréquente au cours de notre étude, constituent une préoccupation du fait de leur fréquence croissante, leur diagnostic souvent tardif et les difficultés liées à leur prise en charge surtout dans nos pays avec une population à faible revenu. La sensibilisation de la population et la prescription plus large de l'endoscopie digestive basse devraient permettre une meilleure prise en charge des patients. Pan African Medical Journal. 2014; 18:26 doi:10.11604/pamj.2014.18.26.3003 This article is available online at: http://www.panafrican-med-journal.com/content/article/18/26/full/ © Alice Nanelin Guingané et al. The Pan African Medical Journal ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Pan African Medical Journal – ISSN: 19378688 (www.panafrican-med-journal.com) Published in partnership with the African Field Epidemiology Network (AFENET). (www.afenet.net) Case series Open Access
Who is eligible for randomized trials? A comparison between the exclusion criteria defined by the ISCHEMIA trial and 3102 real-world patients with stable coronary artery disease undergoing stent implantation in a single cardiology center

BACKGROUND
Randomized controlled trials are the gold standard for evaluating therapy; however, controversy exists regarding the applicability of such results to daily practice, as patients are often pre-selected and may not reflect real-world clinical settings. We studied the eligibility criteria for 3102 "real-life" patients with stable coronary artery disease (SCAD) according to the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial exclusion criteria. The aim of our analysis was to estimate the percentage of real-life patients who would have met the exclusion criteria for the ISCHEMIA trial.


METHODS
We analyzed 3102 patients with SCAD referred to the Silesian Center for Heart Disease who underwent both coronary angiography and stent implantation between January 2006 and December 2011. The patients were divided into two groups. Group A was composed of patients with SCAD who would have been excluded from the ongoing ISCHEMIA trial, whereas group B represented the remaining patients.


RESULTS
A total of 1900 (61.3%) patients met at least one of the exclusion criteria. The most frequent exclusion criterion noted was revascularization within the previous 12 months (938 patients; 49.4%), followed by unacceptable level of angina symptoms (532 patients; 28 %), low ejection fraction (467 patients; 24.6%), and acute coronary syndrome within the previous 2 months (456 patients; 24%). Patients from our cohort who would have been excluded from the ISCHEMIA trial were older, had more comorbidities, and experienced worse long-term outcomes.


CONCLUSIONS
The ISCHEMIA trial exclusion criteria ruled out the majority of the patients with SCAD undergoing percutaneous coronary intervention in "real life". Our cohort of patients who would have been excluded from the ISCHEMIA trial had more comorbidities and experienced significantly worse long-term outcomes than patients who did not meet the ISCHEMIA trial exclusion criteria.


TRIAL REGISTRATION
ClinicalTrials.gov NCT01471522.
Asynchronous object storage with QoS for scientific and commercial big data

This paper presents our design for an asynchronous object storage system intended for use in scientific and commercial big data workloads. Use cases from the target workload domains are used to motivate the key abstractions used in the application programming interface (API). The architecture of the Scalable Object Store (SOS), a prototype object storage system that supports the API's facilities, is presented. The SOS serves as a vehicle for future research into scalable and resilient big data object storage. We briefly review our research into providing efficient storage servers capable of providing quality of service (QoS) contracts relevant for big data use cases.
CT Saturation Calculations: Are They Applicable in the Modern World?—Part I: The Question

Previously, ANSI/IEEE relay current transformer (CT) sizing criteria were based on traditional symmetrical calculations that are usually discussed by technical articles and manufacturers' guidelines. In 1996, IEEE Standard C37.110-1996 introduced (1+X/R) offset multiplying, current asymmetry, and current distortion factors, officially changing the CT sizing guideline. A critical concern is the performance of fast protective schemes (instantaneous or differential elements) during severe saturation of low-ratio CTs. Will the instantaneous element operate before the upstream breaker relay trips? Will the differential element misoperate for out-of-zone faults? The use of electromagnetic and analog relay technology does not assure selectivity. Modern microprocessor relays introduce additional uncertainty into the design/verification process with different sampling techniques and proprietary sensing/recognition/trip algorithms. This paper discusses the application of standard CT accuracy classes with modern ANSI/IEEE CT calculation methodology. This paper is the first of a two-part series; Part II provides analytical waveform analysis discussions to illustrate the concepts conveyed in Part I
Participatory noise pollution monitoring using mobile phones

Noise pollution is a major problem in cities around the world. The current methods to assess it neglect to represent the real exposure experienced by the citizens themselves, and therefore could lead to wrong conclusions and a biased representations. In this paper we present a novel approach to monitor noise pollution involving the general public. Using their mobile phones as noise sensors, we provide a low cost solution for the citizens to measure their personal exposure to noise in their everyday environment and participate in the creation of collective noise maps by sharing their geo-localized and annotated measurements with the community. Our prototype, called NoiseTube, can be found online [1].
Inpatient palliative care for patients with acute heart failure: outcomes from a randomized trial.

BACKGROUND
Heart failure (HF) is associated with a high symptom burden and reduced quality of life (QOL). Models integrating palliative care (PC) into HF care have been proposed, but limited research is available on the outcomes of such models.


OBJECTIVE
Our aim was to assess if inpatient PC for HF patients is associated with improvements in symptom burden, depressive symptoms, QOL, or differential use of services.


METHODS
Patients hospitalized with acute HF were randomized to receive a PC consult with follow-up as determined by provider or standard care. Two hundred thirty-two patients (116 intervention/116 control) from a large tertiary-care urban hospital were recruited over a 10-month period. Primary outcomes were symptom burden, depressive symptoms, and QOL measured at baseline, 1, and 3 months. Secondary outcomes included advance care planning (ACP), inpatient 30-day readmission, hospice use, and death.


RESULTS
Improvements were greater at both 1 and 3 months in the intervention group for primary outcome summary measures after adjusting for age, gender, and marital status differences between study groups. QOL scores increased by 12.92 points in the intervention and 8 points in the control group at 1 month (difference+4.92, p<0.001). Improvement in symptom burden was 8.39 in the intervention group and 4.7 in the control group at 1 month (+3.69, p<0.001). ACP was the only secondary outcome associated with the intervention (hazard ratio [HR] 2.87, p=0.033).


CONCLUSION
An inpatient PC model for patients with acute HF is associated with short-term improvement in symptom burden, QOL, and depressive symptoms.
ShuffleNet: An Extremely Efficient Convolutional Neural Network for Mobile Devices

We introduce an extremely computation-efficient CNN architecture named ShuffleNet, which is designed specially for mobile devices with very limited computing power (e.g., 10-150 MFLOPs). The new architecture utilizes two new operations, pointwise group convolution and channel shuffle, to greatly reduce computation cost while maintaining accuracy. Experiments on ImageNet classification and MS COCO object detection demonstrate the superior performance of ShuffleNet over other structures, e.g. lower top-1 error (absolute 7.8%) than recent MobileNet [12] on ImageNet classification task, under the computation budget of 40 MFLOPs. On an ARM-based mobile device, ShuffleNet achieves ~13Ã— actual speedup over AlexNet while maintaining comparable accuracy.
A comprehensive analog single-event transient analysis methodology

A new method for analyzing analog single-event transient (ASET) data has been developed. The approach allows for quantitative error calculations, given device failure thresholds. The method is described and employed in the analysis of an OP-27 op-amp.
Reduced pre-hospital and in-hospital survival rates after out-of-hospital cardiac arrest of patients with type-2 diabetes mellitus: an observational prospective community-based study.

AIMS
Out-of-hospital cardiac arrest (OHCA) remains a major cause of death. We aimed to determine whether type-2 diabetes mellitus (T2DM) is associated with reduced pre-hospital and in-hospital survival rates after OHCA.


METHODS AND RESULTS
An observational community-based cohort study was performed among 1549 OHCA patients with ECG-documented ventricular tachycardia/ventricular fibrillation (VT/VF). We compared pre-hospital and in-hospital survival rates between T2DM patients and non-diabetic patients. Analyses among T2DM patients were stratified according to current T2DM treatment, used as proxy for T2DM severity. Proportions of neurologically intact survival were analysed. Pre-hospital survival rates were lower in T2DM patients (n = 275) than in non-diabetic patients (n = 1274); 48.7 vs. 55.8% (univariate P = 0.032). Type-2 diabetes mellitus was associated with lower pre-hospital survival [OR 0.75 (0.58-0.98); after evaluation of the risk factors, we found no relevant confounding]. Patients treated with insulin only had lower pre-hospital survival rates than patients treated with oral glucose-lowering drugs only (37.3 vs. 53.3%, univariate P = 0.034), partially explained by location of OHCA and EMS response time [ORadj 0.62 (0.33-1.17)]. In-hospital survival rates were also lower in T2DM patients (n = 134) than in non-diabetic patients (n = 711); 40.3 vs. 57.7%, univariate P < 0.001. In those patients whose cause of OHCA was retrieved (n = 771), T2DM was significantly associated with lower in-hospital survival [ORadj 0.57 (0.37-0.87)]. Neurologically intact status at discharge was similarly high among T2DM and non-diabetic patients (94.4 vs. 94.6%, P = 0.954).


CONCLUSION
T2DM is associated with lower pre-hospital and in-hospital survival rates after OHCA. Neurologically intact status at hospital discharge is high both among T2DM and non-diabetic patients.
Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer

Trials of adjuvant endocrine therapy for breast cancer have shown that aromatase inhibitors have little impact on global health-related quality of life (HRQoL), but have significant effects on patient-reported endocrine symptoms (ESs). There are few studies of HRQoL and psychological distress during preoperative endocrine therapy performed to determine endocrine responsiveness. The NEOS trial is a multicenter, phase 3 randomized controlled trial in postmenopausal women with hormone receptor-positive breast cancer. The primary aim of the trial was to evaluate the need for adjuvant chemotherapy in patients with clinical T1c-T2N0M0, hormone receptor-positive tumors who responded to neoadjuvant letrozole (LET) administered for 24–28 weeks before surgery. The primary endpoint was disease-free survival and the secondary endpoints included adverse events, HRQoL, and cost-effectiveness. In a HRQoL sub-study, subjects were assessed at baseline and 4 and 16 weeks after starting neoadjuvant LET, using the functional assessment of cancer therapy-breast and its ES subscale, and the hospital anxiety and depression scale. HRQoL and psychosocial distress were analyzed in the uncontrolled phase during 24–28 weeks of neoadjuvant LET therapy in the NEOS trial. From May 16, 2008, to December 14, 2011, 503 patients were recruited into the HRQoL sub-study. The full analysis set included 497 patients with a mean age of 63-years old. The questionnaire response rates at enrollment and 4 and 16 weeks were 94.4, 90.7, and 89.1 %, respectively. There were no significant changes in the FACT-G or B-trial outcome index over time, but the social and family well-being score and the ES subscale deteriorated significantly, and the number of patients with clinically significant hot flush increased significantly. Anxiety, depression, and emotional well-being improved significantly after neoadjuvant LET. Neoadjuvant endocrine therapy with LET had no impact on global HRQoL, but did influence endocrine-related symptoms such as hot flush. This study is registered as UMIN000001090.